Table 4.
Win Ratio Analysis.
| n° Pairwise Comparisons | Win Ratio 95%CI p Value |
Net Benefit 95%CI p Value |
Win Odds 95%CI p Value |
% of Winning a | Pairs Tied b | |
|---|---|---|---|---|---|---|
| All patients (403) | 1.47 | 0.11 | 1.25 | |||
| MSS = 351 | 18,252 | 0.91–2.38 | −0.03–0.25 | 0.94–1.65 | MSS = 34 | 7646 |
| MSI = 52 | 0.11 | 0.12 | 0.12 | MSI = 23 | ||
| NonRadical (64) | 1.34 | 0.14 | 1.34 | |||
| MSS = 58 | 348 | 0.39–4.53 | −0.47–0.75 | 0.39–4.5 | MSS = 57 | 3 |
| MSI = 6 | 0.64 | 0.64 | 0.64 | MSI = 42 | ||
| Radical (339) | 2.04 | 0.16 | 1.38 | |||
| MSS = 293 | 13,478 | 1.10–3.79 | 0.02–0.30 | 1.03–1.84 | MSS = 31 | 7207 |
| MSI = 46 | 0.02 | 0.02 | 0.02 | MSI = 15 | ||
| Radical c (339) | 2.20 | 0.17 | 1.42 | |||
| MSS = 293 | 13,478 | 1.15–4.21 | 0.02–0.33 | 1.05–1.92 | MSS = 32 | 7207 |
| MSI = 46 | 0.01 | 0.02 | 0.02 | MSI = 14 | ||
| Radical | ||||||
| AdjCH = No | ||||||
| (182) | 1.37 | 0.05 | 1.10 | |||
| MSS = 160 | 3520 | 0.47–3.98 | −0.12–0.21 | 0.79–1.53 | MSS = 18 | 2432 |
| MSI = 22 | 0.56 | 0.57 | 0.57 | MSI = 13 | ||
| Radical | ||||||
| AdjCH = Yes | ||||||
| (157) | 2.47 | 0.26 | 1.69 | |||
| MSS = 133 | 3192 | 1.16–5.23 | 0.03–0.49 | 1.07–2.67 | MSS = 43 | 1254 |
| MSI = 24 | 0.01 | 0.02 | 0.02 | MSI = 17 | ||
| Propensity (138) | 2.61 | 0.20 | 1.49 | |||
| MSS = 92 | 4232 | 1.27–5.37 | 0.04–0.36 | 1.08–2.06 | MSS = 32 | 2.349 |
| MSI = 46 | 0.009 | 0.01 | 0.01 | MSI = 12 | ||
| Propensity c (138) | 2.76 | 0.21 | 1.53 | |||
| MSS = 92 | 4232 | 1.32–5.78 | 0.04–0.37 | 1.10–2.12 | MSS = 33 | 2.349 |
| MSI = 46 | 0.007 | 0.01 | 0.01 | MSI = 12 |
Win Ratio: ratio between winners and losers in all non-tied pairwise comparisons. The value of 1.00 means that there are neither winners nor losers. Net Benefit: percentage with which one group has a better win ratio than the other group. Win Odds: probability of a group winning over the other group. a percentage of pairwise comparisons won by MSS and MSI tumors, respectively. b number of pairwise comparisons without winners or losers. c primary event was tumor recurrence; the secondary event was death.